首页> 外文OA文献 >Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2)

【2h】

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2)

机译：在法国前瞻性队列研究中，系统性的EGFR和KRAS突变评估对厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存和总体生存的影响（ERMETIC项目第2部分）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Cadranel, Jacques; Mauguen, Audrey; Faller, Michele M.; Zalcman, Gérard G.; Buisine, Marie-Pierre; Westeel, Virginie; Longchampt, Elisabeth E.; Wislez, Marie M.; Coudert, Bruno; Daniel, Catherine C.; Chetaille, Bruno B.; Michiels, Stefan; Blons, Helene H.; Solassol, Jerome J.; De Fraipont, Florence F.; Foucher, Pascal P.; Urban, Thierry T.; Lacroix, Ludovic L.; Poulot, Virginie V.; Quoix, Elisabeth; Antoine, Martine; Danton, Guillaume G.; Morin, Franck; Chouaid, Christos C.; Pignon, Jean Pierre;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2) [J] . CadranelJ., MauguenA., FallerM., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第10期

机译：在法国前瞻性队列研究中，系统性的EGFR和KRAS突变评估对厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存和总体生存的影响（ERMETIC项目第2部分）
2. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) [J] . Beau-Faller Michele, Texier Matthieu, Blons Helene, Clinical lung cancer . 2019,第3期

机译：EGFR或KRAS-yras-yran-yration患者在法国预期队列中orlotinib患者患者患者的临床相关性（IFCT ERMICEM2 COHORT - 第2部分）
3. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors [J] . Imai Hisao, Yamada Yutaka, Sugiyama Tomohide, Chemotherapy: International Journal of Experimental and Clinical Chemotherapy . 2018,第3期

机译：患有一线EGFR酪氨酸激酶抑制剂治疗的患有敏感EGFR突变的老年非小细胞肺癌患者整体生存的临床影响
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations [O] . Mo Tang, Shumei Wang, Bin Zhao, 2019

机译：中药可延长表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的非小细胞肺癌（NSCLC）携带EGFR突变的患者的无进展生存期并增强治疗效果
6. Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2) [O] . Cadranel Jacques, Mauguen Audrey, Faller Michele, 2012

机译：系统性EGFR和KRAS突变评估对法国前瞻性队列研究中厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存期和总生存期的影响（ERMETIC项目-第2部分）

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2)

著录项

引文网络

相似文献

相关主题

期刊订阅